Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results
Business Wire•05/11/2026•16:05 ET
0
Key Highlights
- ➤NANOPULSE-AF enrollment completed with 169 evaluable patients across 15 sites and 36 investigators
- ➤Cash, equivalents, and marketable securities reached $189.2 million, up from $101.6 million sequentially
- ➤ATM programs generated $95.8 million net proceeds in Q3, with under 6% dilution
- ➤Third-quarter revenue rose to $0.4 million from $0.1 million year over year
- ➤Third-quarter GAAP net loss widened to $23.1 million from $19.4 million
Expert Statements
Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences
“Pulse Biosciences delivered several major milestones since the second quarter, led by completing enrollment in our U.S. pivotal IDE study in just six months, three months ahead of plan. That speed reflects the growing enthusiasm physicians have shown for the nPulse catheter since their very first cases. We also meaningfully strengthened our balance sheet, represented by institutional investor conviction in the opportunities ahead enabled by our technology and our team. With NANOPULSE-AF fully enrolled, and the capital to execute, we are now focused on preparations for launch readiness, additional data readouts, and regulatory submissions. We are also advancing new clinical study initiatives and exciting product development innovations, reflecting the deep application pipeline for our platform technology that gives us the opportunity to bring nsPFA to very large, underserved patient populations.”
Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results
Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System
Get started
Create a free account to read the full story.